Current therapeutic strategies for IBD, including biologics targeting inflammatory cytokines (e.g., anti-TNF-α agents) and immunosuppressants, are limited by systemic side effects, variable efficacy, and failure to address underlying epithelial barrier dysfunction [35]. This evidence concerns the gene TNF and inflammatory bowel disease.